Me-lex py/py , an adenine-N3-selective alkylating agent, and the reversible minor-groove binder netropsin were used to probe the formation of unusual minor-groove adducts by the cytotoxic hybrid agent PT-ACRAMTU ([PtCl(en)(ACRAMTU)](NO 3 ) 2 ; en ) ethane-1,2-diamine, ACRAMTU ) 1-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea). PT-ACRAMTU was found by chemical footprinting to inhibit specific Me-lex-mediated DNA cleavage at several adenine sites but not at nonspecific guanine, which is consistent with the platination of adenine-N3. In a cell proliferation assay, a significant decrease in cytotoxicity was observed for PT-ACRAMTU, when cancer cells were pretreated with netropsin, suggesting that minor-groove adducts in cellular DNA contribute to the biological activity of the hybrid agent.
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The development of nonclassical platinum-containing drugs in recent years that interact with DNA radically differently than cis-diamminedichloroplatinum(II) (cisplatin 1 ) (1) requires novel biochemical tools to study the DNA damage caused by these agents and their biological effects. One such compound, PT-ACRAMTU ([PtCl(en)(ACRAMTU)](NO 3 ) 2 ; en ) ethane-1,2-diamine, ACRAMTU ) 1-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea); Chart 1) and its derivatives have demonstrated promising activity in chemoresistant cancers (2, 3) . Structureactivity relationship studies suggest that the cytotoxic effect of the platinum-acridines is mediated by DNA adducts (2, (4) (5) (6) . Unlike cisplatin, PT-ACRAMTU and its derivatives do not induce nucleobase-nucleobase cross-links but form monofunctional-intercalative DNA adducts. The DNA damage profile of PT-ACRAMTU differs significantly from that of clinical platinum-based drugs. While the latter agents primarily target sequences of contiguous guanine (G) bases (7), the hybrid agent's adducts form with single G bases at pyrimidine-purine steps, and with adenine (A), mainly at 5′-TA sites (5, 8) . The most striking DNA-binding feature of PT-ACRAMTU proved to be its ability to form adducts with A-N3, a binding mode previously unknown in platinum-DNA interactions (3) .
We previously demonstrated that more than 30% of the adenine adducts are formed with the minor-groove site, A-N3, but the local sequence context of these adducts remained elusive (3) . On the basis of the presence of the platinated deoxydinucleotide fragment d(TpA*) in mixtures of enzymatically digested drug-modified DNA, we proposed that PT-ACRAMTU forms adducts in the minor groove in this specific sequence (9) . The reasoning behind this explanation was that platination of A-N3 might interfere with the DNA cleavage chemistry of DNase I, the minor-groove binding endonuclease (10) used in our assay, resulting in the undigested, platinated deoxydinucleotide.
To test our hypothesis of minor-groove platination in TArich sequences, we took advantage of two DNA minor-groove directed agents, the dipyrroledipeptide-methylsulfonate ester conjugate Me-lex py/py , a minor-groove-specific alkylating agent (11) (12) (13) (14) , and netropsin, the classical dipyrroledipeptide natural product (15) (Chart 1). The data presented here suggest that in a synthetic 46-base-pair DNA fragment treated with PT-ACRAMTU, platinum efficiently protects A-N3 from methylation by Me-lex py/py , providing evidence for platinum binding to this site. Additionally, a cell proliferation assay was performed, demonstrating that netropsin partially protects cancer cells from PT-ACRAMTU (but not from cisplatin), corroborating the notion that A-N3 adducts form intracellularly and contribute to the cytotoxic effect of the hybrid agent.
Alkylating agents have potential applications in probing the sequence and base selectivity of DNA interactive molecules (16) (17) (18) . Me-lex py/py methylates A-N3 in double-stranded DNA with high selectivity (14) . This produces 3-methyladenine (3-MeA) in TA-rich sequence contexts. 3-MeA is a labile adduct, which undergoes thermal depurination. Subsequent base treatment leads to single-strand breaks, which can be monitored in radioactively labeled DNA fragments by polyacrylamide gel electrophoresis (PAGE).
The footprinting assay reported here is based on the expectation that platination of A-N3 will protect this minor-groove site from alkylation by Me-lex py/py , ultimately inhibiting the DNAcleavage chemistry of the methylating agent. Thus, platination of Me-lex-specific A-N3 prior to treatment of the probe sequence with the minor-groove alkylator should result in a weakening or complete disappearance of the corresponding band on the gel. (Unlike 3-MeA, heat-induced depurination of platinated adenine is not observed under the conditions of this assay (19 
sequences in which the A base directly adjacent to T showed the highest propensity for 3-MeA formation (14) . Since the 5′-TA step is also targeted by PT-ACRAMTU (8, 9), we designed a DNA fragment containing the above high-affinity sites to detect the formation of A-N3 adducts in this sequence context.
The 46-base-pair sequence, whose top strand (46top, Figure  1B ) was 5′ end-labeled with 32 P, was incubated with four different concentrations of PT-ACRAMTU, treated with Melex py/py , and subjected to piperidine cleavage after the removal of bound platinum. The resulting fragments were then identified and quantified by running the samples on a denaturing polyacrylamide gel along G and G + A sequencing lanes, as well as Me-lex-only footprinting lanes. The DNA fragment was modified with platinum at drug-to-nucleotide ratios of 0.022, 0.044, 0.087, and 0.13 (lanes Pt1-Pt4, Figure 1A ), assuming that platinum binding is complete after 24 h (8), which corresponds to a total of 6 adducts per double-stranded fragment at the highest drug concentration.
To test the alkylation activity of Me-lex py/py in the absence of platinum, the 46-base-pair sequence was incubated with 20 µM and 50 µM alkylating agent, respectively (lanes ML and MH in Figure 1A) . The strongest damage caused by Me-lex py/py in the portion of 46top suitable for monitoring nucleobase alkylation (A8-G33) was observed at adenine residues A27-A29. When the fragment was incubated at a concentration of 50 µM, the minor-groove alkylator had a higher affinity for the adenine triplet than for the two adjacent A bases, A8 and A9. The agent also caused damage at A31 and at several G bases, the latter resulting from nonspecific alkylation, which is in agreement with the damage profile reported in the literature (14) .
Pretreatment of the probe sequence with PT-ACRAMTU has a dramatic effect on the alkylation chemistry of Me-lex py/py at A8, A9, A27-A29, and A31. Cleavage is significantly reduced at these sites as evidenced by a gradual decrease of the corresponding band intensities on the gel with increasing platinum concentration (Pt1-Pt4, Figure 1A ). This confirms that PT-ACRAMTU and Me-lex py/py target adenine bases with the same sequence specificity and comparable affinity. The pronounced inhibitory effect of PT-ACRAMTU on A-N3 alkylation is consistent with the formation of platinum adducts with the minor-groove donor. By contrast, the bands resulting from nonspecific, Me-lex-initiated cleavage at G residues show no decrease in intensity. Cleavage at G13 and G15, for instance, is completely unaffected by platination, which is surprising because PT-ACRAMTU has been shown to target 5′-TG sites (5) . Since G is the major target for PT-ACRAMTU (∼80%) (9) but only a minor target for Me-lex py/py (∼10%) (14) , platinum might be expected to interfere with the alkylation chemistry of the minor-groove binder, which is not the case. This suggests that depurination of G in this sequence context is mediated by minor-groove alkylation of G-N3, which does not seem to be affected by the platinum adducts formed exclusively with G-N7 in the major groove. (While methylation of G-N3 by Me-lex py/py is feasible (14) , platination of this site is sterically prohibited (3).)
To test our hypothesis that PT-ACRAMTU forms minor-groove adducts in nuclear DNA, which might contribute to the cytotoxic effect of this agent, we designed a cell protection assay. The design is based on the supposition that minor-groove binders should compete with PT-ACRAMTU for minor-groove binding sites, thereby preventing the platination of A-N3. Since Me-lex py/py itself is very cytotoxic (13), a less toxic, noncovalent binder, netropsin (Chart 1), was chosen in this study. (Netropsin has previously been used to demonstrate that methylation of A-N3 by Me-lex py/py is the major cause of the alkylating agent's cell toxicity (20) .) The cell line chosen for this experiment is NCI-H460, a nonsmall cell lung cancer, which has proven highly sensitive to PT-ACRAMTUtype agents. To determine if netropsin can be used as a modulator of cytotoxicity in this assay, NCI-H460 cells were incubated with the minor-groove binder for 72 h in the absence of the platinum drug. It was confirmed that netropsin itself does not affect H460 cell proliferation at concentrations below 50 µM. H460 cells were treated for 72 h with PT-ACRAMTU and, in a control experiment, with cisplatin, both in the absence of netropsin and at three concentrations (6.25, 12.5, and 25 µM) of netropsin that have no effect on cell survival. Selected drug-response curves are shown in Figure 2 . In the absence of netropsin, an IC 50 value of 0.068 ( 0.003 µM was calculated for PT-ACRAMTU. In the presence of the minor-groove binder, PT-ACRAMTU's cell kill efficiency decreases, resulting in higher IC 50 values. At 25 µM netropsin, a statistically significant (P < 0.05) higher concentration of PT-ACRAMTU (0.163 ( 0.013 µM) is needed compared to that of netropsin-free H460 to inhibit cell proliferation by 50%. These results suggest that a relationship exists between PT-ACRAMTU's ability to interact with the minor groove in nuclear DNA and the drug's cell kill potential. By contrast, cisplatin in netropsin-treated . These findings are in agreement with the fact that while PT-ACRAMTU and netropsin target common regions in nuclear DNA, cisplatin (G, major groove) and netropsin (A, minor groove) target DNA at mutually exclusive sites. PT-ACRAMTU is the only platinum agent known to date that targets TA-rich sequences. However, several bioactive A-N3 alkylating natural and synthetic DNA binders exist, such as bizelesin, a hypercytotoxic bifunctional chloromethyl derivative of the family of cyclopropylpyrroloindole antitumor antibiotics (21) . Bizelesin induces long-range A-N3/A-N3 interstrand crosslinks in untranscribed, adenine-rich regions (AT islands) of the genome known as matrix attachment regions (MARs) (22) (23) (24) . MARs play important roles in chromatin organization and gene expression, and disruption of MAR function has been shown to stall cell proliferation (22) . The potent antiproliferative properties of PT-ACRAMTU may be, in part, due to the formation of adducts in these sequences. The decrease in cytotoxicity of PT-ACRAMTU in the presence of netropsin at noncytotoxic concentrations supports this notion. Future work will explore the possibility of using Me-lex py/py to detect platinum-modified A-N3 in nuclear DNA extracted from drugtreated cells.
